We are happy and proud to announce, that the CRC 992 “Medical Epigenetics – From basic mechanisms to clinical applications” receives funding for another 4 years from the DFG. The DFG senate has decided to extend the funding of the CRC 992 with aprox. 14 Million Euros.
Epigenetics focuses on mechanisms of heredity, which go beyond the genetic determination. Proteins thereby determine which parts of the genetic code of a cell will be accessed for a specific function – similar as to how bookmarks ensure that the right pages of a book are found. The analysis and interpretation of epigenetic patterns can help to better understand the development of diseases. The long term goal of the CRC 992 is to improve the diagnosis and treatment of various diseases. Speaker is Prof. Dr. Roland Schüle, Scientific Director of the Department of Urology and Head of the Centre for Clinical Research at the University Medical Center Freiburg. Other scientists from different institutions and departments of the University of Freiburg, the University Medical Center Freiburg and the Max Planck Institute of Immunobiology and Epigenetics in Freiburg are involved in the project. ”The continuation of the CRC 992 is another milestone for epigenetic research in Freiburg. The extension of the grant is a reward for the excellent research in the projects during the first and second funding period, ” said Schüle. „Furthermore, this is an incentive to continue this approach in order to achieve our goal of a Centre of Excellence in translational epigenetic research.”
Press releases:
https://www.dfg.de/en/service/press/press_releases/2020/
https://www.pr.uni-freiburg.de/pm/2020/stark-im-verbund
https://www.uniklinik-freiburg.de/presse/pressemitteilungen/
